{"success":true,"data":{"pressRelease":{"id":"32788","rtpr_id":"nGNX34ZWzY","ticker":"ASMB","exchange":"NASDAQ","all_tickers":["ASMB"],"title":"Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026","author":"Globe Newswire","published_at":"2026-05-13T06:00:00.144Z","article_body":"SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly\nBiosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing\ninnovative therapeutics targeting serious viral diseases, today announced\ntopline clinical data on ABI-6250, an investigational oral hepatitis D virus\n(HDV) entry inhibitor, will be presented in a poster presentation at the\nEuropean Association for the Study of the Liver (EASL) Congress taking place\nMay 27-30, 2026, in Barcelona, Spain.\n\n“We are pleased to present additional Phase 1a data on ABI-6250 at EASL,”\nsaid Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “As the\nonly oral entry inhibitor currently in clinical development for chronic\nhepatitis D, ABI-6250 is designed to offer a differentiated approach, and\nthese data further support our plan to advance directly into a Phase 2 study\nby year-end.”\n\nThe presentation will feature results from a randomized, blinded, Phase 1a\nstudy evaluating the safety, pharmacokinetics and pharmacodynamic activity of\nABI-6250 following single- and multiple-dose administration in healthy\nparticipants.\n\nPresentation details are as follows:\n\nTitle: Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a\nFirst-in-Class Oral Hepatitis D Virus Entry Inhibitor, in Healthy Subjects:\nInterim Results From a Randomized, Blinded, Phase 1a Study\nPresenter: Edward J. Gane, MD, University of Auckland\nPoster Number: WED-579\nSession: Viral Hepatitis B and D: New therapies, unapproved therapies or\nstrategies\nDate: Wednesday, May 27, 2026\n\nAssembly Bio intends to make the poster available on the “Events &\nPresentations” page in the “Investors” section and on the\n“Publications” page in the “Pipeline” section of its website at\nwww.assemblybio.com.\n\nABI-6250 is an investigational product candidate that has not been approved\nanywhere globally, and its safety and efficacy has not been established.\n\nAbout Assembly Biosciences \nAssembly Biosciences is a biotechnology company dedicated to the development\nof innovative small-molecule therapeutics designed to change the path of\nserious viral diseases and improve the lives of patients worldwide. Led by an\naccomplished team of leaders in virologic drug development, Assembly Bio is\ncommitted to improving outcomes for patients struggling with the serious,\nchronic impacts of herpesvirus, hepatitis B virus (HBV) and HDV infections.\nFor more information, visit assemblybio.com.\n\nForward-Looking Statements\nThe information in this press release contains forward-looking statements that\nare subject to certain risks and uncertainties that could cause actual results\nto materially differ. These risks and uncertainties include: Assembly Bio’s\nability to realize the potential benefits of its collaboration with Gilead,\nincluding all financial aspects of the collaboration and equity investments;\nAssembly Bio’s ability to initiate and complete clinical studies involving\nits therapeutic product candidates, including studies contemplated by Assembly\nBio’s collaboration with Gilead, in the currently anticipated timeframes or\nat all; safety and efficacy data from clinical or nonclinical studies may not\nwarrant further development of Assembly Bio’s product candidates; clinical\nand nonclinical data may not differentiate Assembly Bio’s product candidates\nfrom other companies’ candidates; Assembly Bio’s ability to maintain\nfinancial resources and secure additional funding necessary to continue its\nresearch activities, clinical studies, and other business operations;\npotential effects of changes in government regulation; results of nonclinical\nstudies may not be representative of disease behavior in a clinical setting\nand may not be predictive of the outcomes of clinical studies; and other risks\nidentified from time to time in Assembly Bio’s reports filed with the U.S.\nSecurities and Exchange Commission (the SEC). You are urged to consider\nstatements that include the words may, will, would, could, should, might,\nbelieves, hopes, estimates, projects, potential, expects, plans, anticipates,\nintends, continues, forecast, designed, goal or the negative of those words or\nother comparable words to be uncertain and forward-looking. Assembly Bio\nintends such forward-looking statements to be covered by the safe harbor\nprovisions contained in Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. More\ninformation about Assembly Bio’s risks and uncertainties are more fully\ndetailed under the heading “Risk Factors” in Assembly Bio’s filings with\nthe SEC, including its most recent Annual Report on Form 10-K, Quarterly\nReports on Form 10-Q and Current Reports on Form 8-K. Except as required by\nlaw, Assembly Bio assumes no obligation to update publicly any forward-looking\nstatements, whether as a result of new information, future events or\notherwise.\n\nContacts:\n\nInvestors:\nPatrick Till\nMeru Advisors\n(484) 788-8560\ninvestor_relations@assemblybio.com\n\nMedia:\nSam Brown LLC\nJamie Strachota\n(703) 819-7647\nASMBMedia@sambrown.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/33089548-b62b-412d-9343-ae38d8b720c6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX34ZWzY","title":"Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026","author":"Globe Newswire","ticker":"ASMB","created":"2026-05-13T06:00:00.144Z","tickers":["ASMB"],"exchange":"NASDAQ","article_body":"SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly\nBiosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing\ninnovative therapeutics targeting serious viral diseases, today announced\ntopline clinical data on ABI-6250, an investigational oral hepatitis D virus\n(HDV) entry inhibitor, will be presented in a poster presentation at the\nEuropean Association for the Study of the Liver (EASL) Congress taking place\nMay 27-30, 2026, in Barcelona, Spain.\n\n“We are pleased to present additional Phase 1a data on ABI-6250 at EASL,”\nsaid Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “As the\nonly oral entry inhibitor currently in clinical development for chronic\nhepatitis D, ABI-6250 is designed to offer a differentiated approach, and\nthese data further support our plan to advance directly into a Phase 2 study\nby year-end.”\n\nThe presentation will feature results from a randomized, blinded, Phase 1a\nstudy evaluating the safety, pharmacokinetics and pharmacodynamic activity of\nABI-6250 following single- and multiple-dose administration in healthy\nparticipants.\n\nPresentation details are as follows:\n\nTitle: Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a\nFirst-in-Class Oral Hepatitis D Virus Entry Inhibitor, in Healthy Subjects:\nInterim Results From a Randomized, Blinded, Phase 1a Study\nPresenter: Edward J. Gane, MD, University of Auckland\nPoster Number: WED-579\nSession: Viral Hepatitis B and D: New therapies, unapproved therapies or\nstrategies\nDate: Wednesday, May 27, 2026\n\nAssembly Bio intends to make the poster available on the “Events &\nPresentations” page in the “Investors” section and on the\n“Publications” page in the “Pipeline” section of its website at\nwww.assemblybio.com.\n\nABI-6250 is an investigational product candidate that has not been approved\nanywhere globally, and its safety and efficacy has not been established.\n\nAbout Assembly Biosciences \nAssembly Biosciences is a biotechnology company dedicated to the development\nof innovative small-molecule therapeutics designed to change the path of\nserious viral diseases and improve the lives of patients worldwide. Led by an\naccomplished team of leaders in virologic drug development, Assembly Bio is\ncommitted to improving outcomes for patients struggling with the serious,\nchronic impacts of herpesvirus, hepatitis B virus (HBV) and HDV infections.\nFor more information, visit assemblybio.com.\n\nForward-Looking Statements\nThe information in this press release contains forward-looking statements that\nare subject to certain risks and uncertainties that could cause actual results\nto materially differ. These risks and uncertainties include: Assembly Bio’s\nability to realize the potential benefits of its collaboration with Gilead,\nincluding all financial aspects of the collaboration and equity investments;\nAssembly Bio’s ability to initiate and complete clinical studies involving\nits therapeutic product candidates, including studies contemplated by Assembly\nBio’s collaboration with Gilead, in the currently anticipated timeframes or\nat all; safety and efficacy data from clinical or nonclinical studies may not\nwarrant further development of Assembly Bio’s product candidates; clinical\nand nonclinical data may not differentiate Assembly Bio’s product candidates\nfrom other companies’ candidates; Assembly Bio’s ability to maintain\nfinancial resources and secure additional funding necessary to continue its\nresearch activities, clinical studies, and other business operations;\npotential effects of changes in government regulation; results of nonclinical\nstudies may not be representative of disease behavior in a clinical setting\nand may not be predictive of the outcomes of clinical studies; and other risks\nidentified from time to time in Assembly Bio’s reports filed with the U.S.\nSecurities and Exchange Commission (the SEC). You are urged to consider\nstatements that include the words may, will, would, could, should, might,\nbelieves, hopes, estimates, projects, potential, expects, plans, anticipates,\nintends, continues, forecast, designed, goal or the negative of those words or\nother comparable words to be uncertain and forward-looking. Assembly Bio\nintends such forward-looking statements to be covered by the safe harbor\nprovisions contained in Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. More\ninformation about Assembly Bio’s risks and uncertainties are more fully\ndetailed under the heading “Risk Factors” in Assembly Bio’s filings with\nthe SEC, including its most recent Annual Report on Form 10-K, Quarterly\nReports on Form 10-Q and Current Reports on Form 8-K. Except as required by\nlaw, Assembly Bio assumes no obligation to update publicly any forward-looking\nstatements, whether as a result of new information, future events or\notherwise.\n\nContacts:\n\nInvestors:\nPatrick Till\nMeru Advisors\n(484) 788-8560\ninvestor_relations@assemblybio.com\n\nMedia:\nSam Brown LLC\nJamie Strachota\n(703) 819-7647\nASMBMedia@sambrown.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/33089548-b62b-412d-9343-ae38d8b720c6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-13T06:00:00.352966213Z","server_sent_at_ms":1778652000352},"received_at":"2026-05-13T06:00:00.480Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}